As an early investor in Dyne Therapeutics, CureDuchenne is happy to share that new analyses out to 24 months showed improvement in heart and lung function with z-rostudirsen compared to declines observed in published Duchenne natural history data.
Link to press release: https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-announces-new-positive-cardiopulmonary-results
The post Dyne reports cardiopulmonary benefits in Duchenne trial of z-rostudirsen in individuals amenable to skipping exon 51 appeared first on CureDuchenne.